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Abstract: In a group of IVF/ICSI cycles, despite the appropriate ovarian stimulation, the number of oocytes collected is below the
expected value. This condition is defined as poor ovarian response (POR) to stimulation. POR brings the risk of cycle cancellation
with an estimated rate of 20%. Infertility experts are trying to improve cycle outcomes of POR cases with multiple modifications. This
review article will present the latest modifications on the management of POR. The studies performed for improving cycle outcome
in POR cases were evaluated and their notable results were presented. The first intervention among infertility specialists is to make
a standard definition for POR. The BOLOGNA criteria and the subsequent POSEIDON group definitions are the latest updates in
POR management. GnRH antagonists, estradiol priming, double stimulation, letrozole administration, DHEA, and herbal therapy
supplementations are the recent modifications done to improve oocyte retrieval and subsequent embryo transfer for POR cases. This
review article presents the encouraging methods applied for POR cases to improve cycle outcome.
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1. Introduction
The success of in vitro fertilization/intracytoplasmic
sperm injection (IVF/ICSI) cycles are firstly dependent
on the number of collected mature oocytes. Enough
mature oocytes start the possibility of enough qualified
embryos for transfer [1]. Low mature oocyte number
due to decreased ovarian reserve (DOR) is one of the
success-limiting factors for IVF/ICSI cycle outcomes [2].
Improving the cycle outcome is one of the struggle of
infertility experts.
It is known that advanced maternal age is a predictor
of DOR. Surgical interventions, especially endometrioma
extirpation from ovarian tissue, and chemotherapy,
radiation therapy, and smoking are prominent factors
decreasing ovarian follicular reserve. Genetic factors such
as premature menopause or premature ovarian failure and
follicle-stimulating hormone (FSH) receptor mutations
are the other etiological factors of diminished ovarian
oocyte pool [3,4].
In a group of IVF/ICSI cycles, despite appropriate
ovarian stimulation, the number of oocytes collected is
below the expected value. This condition is defined as poor
ovarian response (POR) to stimulation. The incidence of
poor responders in IVF/ICSI cycles approximately varies
between 9% and 25% [5,6]. Poor response brings the risk
of cycle cancellation with an estimated rate of 20% [7].

2. Definitions
Due to heterogeneous risk factors, there is not a distinct
definition for POR. Researchers and committees have
issued opinions for standardization. In 2011, The ESHRE
consensus conference published the BOLOGNA criteria
for definition of POR as the presence of two of the
following criteria: 1) advanced maternal age (≥40 years) or
any other risk factor for POR, 2) a previously characterized
POR cycle (≤3 oocytes with a conventional stimulation
protocol), 3) an abnormal ovarian reserve test (antral
follicle count <5–7 follicles or AMH <0.5–1.1 ng/mL) [8].
Among the ovarian reserve tests, there are antral follicle
count (AFC), FSH, anti-Müllerian hormone (AMH),
inhibin B, and ovarian volume, but AMH, FSH, and AFC
are the most sensitive ones [9]. In addition, two cycles with
retrieval of three oocytes or less after maximal stimulation
are enough to classify a patient as a poor responder, even
in the absence of the other two criteria of BOLOGNA.
Some researchers have criticized the BOLOGNA criteria
for the heterogeneity of the patient population [8,10,11].
Classification according to retrieved oocyte number
brings four groups as follows: 1) Suboptimal response:
retrieval of four to nine oocytes; 2) Normal responders:
retrieval of 10–15 oocytes; 3) Hyperresponders: retrieval
of more than 15 oocytes; 4) low responders: retrieval of
fewer than 4 oocytes [12].
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Recently the POSEIDON (Patient-Oriented Strategies
Encompassing
Individualized
Oocyte
Number)
group reported a new approach for the definition and
management of patients suffering from POR [13]. Their
final aim was to determine the ideal stimulation for
obtaining a euploid embryo for a successful transfer. This
new approach classified the low responder women into four
groups according to age, ovarian reserve, and stimulation
response with the aim of determining the prognosis.
Group 1: Patients younger than 35 with sufficient
ovarian reserve parameters (AFC ≥5, AMH ≥1.2 ng/
mL) and with an unexpected poor or suboptimal ovarian
response;
Subgroup 1a: <4 oocytes retrieved.
Subgroup 1b: 4–9 oocytes retrieved.
Group 2: Patients older than 35 with sufficient ovarian
reserve parameters (AFC >5, AMH >1.2 ng/mL) and with
an unexpected poor or suboptimal ovarian response;
Subgroup 2a: 4 oocytes retrieved.
Subgroup 2b: 4–9 oocytes retrieved.
Group 3: Patients younger than 35 with poor ovarian
reserve parameters (AFC <5, AMH <1.2 ng/mL).
Group 4: Patients older than 35 with poor ovarian
reserve parameters (AFC <5, AMH <1.2 ng/mL).
With this concept, low responders were defined as
having poor prognosis. Age is the main predictor for IVF/
ICSI cycle outcome because the older age brings DOR
with decreased oocyte quality. Researchers observed lower
pregnancy rates in older POR patients compared to that in
younger POR patients [4].
3. Treatment modalities
Increasing gonadotropin doses in stimulation protocols
is the first step used by all clinicians for poor responders.
It was reported that there was no difference among
300–450 and 600 units of gonadotropins for IVF/ICSI
cycle outcomes in poor responders [14]. It was accepted
that long pituitary suppression with a GnRH agonist is
detrimental for the oocyte pools of DOR cases. Due to this
condition, microdose flare-up and short-flare protocols
were developed for women suffering from POR [15].
Pituitary downregulation with GnRH antagonists
is the second step to improve the cycle outcome in POR
[16–18], but studies indicate that there is not a significant
improvement in cycle outcomes with GnRH antagonists
compared to agonist cycles [19–21].
The addition of growth hormones, transdermal
testosterone, L-arginine, and pyridostigmine are
experimental modifications that have been shown to not
improve cycle outcomes in POR [22–25].
3.1. Stimulation modifications
Luteal estradiol (LE) priming is one of the other
experimental modifications applied for POR to improve

960

hypothalamic–pituitary–ovarian axis function [26].
Generally, LE priming is initiated on the 20th day of the
previous cycle by daily administration of 4 mg of oral
estradiol supplement or 0.1 mg of estradiol patch every
other day, and is continued until day 2 of the following
menstruation [27]. Supplementation of 4 mg of oral
estradiol during the luteal phase combined with a short
GnRH agonist protocol did not improve pregnancy rates
compared to a long agonist protocol primed with oral
contraceptive pills [28]. Metaanalysis showed that LE
primed cycles had lower cancellation risk with improved
clinical pregnancy rates compared to non-LE primed
cycles despite no improvement on collected mature oocyte
numbers and number of embryos per cycle [27].
Midfollicular recombinant luteinizing hormone (rLH)
or urinary human chorionic gonadotrophin (HCG)
supplementation is another experimental modification
applied to improve retrieved oocytes in POR cases during
antagonist cycles [29].
3.2. Double stimulation/Shanghai protocol
Researchers modify ovarian stimulation with a GnRH
antagonist in different steps for POR. The first step is
to combine gonadotropins with antiestrogenic agents
such as clomiphene or letrozole. The second step is a
GnRH agonist trigger combined with ibuprofen for final
maturation before oocyte retrieval. For follicles with a
diameter greater than 17 mm, oocytes are retrieved and
embryo freezing is performed. The third step is luteal
gonadotropin stimulation with an antiestrogenic agent
with GnRH antagonist for follicles smaller than 13 mm in
diameter. The fourth step is agonist trigger with ibuprofen
again. The fifth step is endometrial preparation for frozenthawed embryo transfer. This stimulation type gives the
opportunity of more oocyte retrieval without improvement
in live birth rate in POR [30,31].
3.3. Aromatase inhibitors
Letrozole is an aromatase inhibitor first applied for breast
cancer for the decrement of estrogen levels. Decrement of
estrogen levels results in increment of androgen levels. This
microenvironment induces endogenous gonadotropin
secretion and, according to this result, letrozole is being
used for ovulation induction especially in POR [32].
Researchers reported improved cycle outcomes in
gonadotropin dose decrement with letrozole combination
compared to high-dose gonadotropin administration for
POR [33].
4. Supplemental therapies
Dehydroepiandrosterone (DHEA) is a steroid prohormone
originating from ovarian theca cells and the adrenal cortex
[34]. DHEA is an androgenic supplement given to improve
the number of oocytes collected in POR [35]. While
some researchers reported improvement with DHEA
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supplementation on clinical pregnancy rates, live birth
rate, endometrial thickness, and retrieved oocyte number
[36], other researchers did not report improvement in
cycle outcomes with DHEA supplementation [37].
The Kuntai capsule is one of the recent herbal therapy
components of Chinese medicine applied for premature
menopause. A Kuntai capsule consists of six traditional
Chinese herbs, including Radix Rehmanniae Preparata,
Rhizoma Coptidis, Radix Paeoniae Alba, Donkey Hide
Gelatin, Radix Scutellariae, and Poria. In an experimental

premature menopause model, researchers showed
improvement in number of antral follicles with Kuntai
capsule treatment [38]. Lian and Jing observed increment
of retrieved oocyte numbers and high-quality embryos in
POR cases after Kuntai capsule treatment [39].
5. Conclusion
Despite the multiple modifications of stimulation protocols
and dietary intake presented here, POR remains a hard
problem for infertility experts to solve.
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